Want to see IN:BLISSGVS full AI Analyst Report?
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹118.35 - ₹552.90
Previous CloseN/A
Volume571.01K
Average Volume (3M)104.36K
Market Cap
₹49.57B
Enterprise Value₹21.82K
Total Cash (Recent Filing)₹1.89B
Total Debt (Recent Filing)₹217.50M
Price to Earnings (P/E)38.4
Beta1.24
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)12.13
Shares Outstanding106,056,220
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow and declining debt with rising equity and assets provides durable financial flexibility for a pharma manufacturer. It supports funding regulatory approvals, capacity maintenance or expansion, and absorbs project timing shocks without heavy reliance on external financing over the next 2–6 months.
Export Exposure To Regulated MarketsHaving sales into regulated and semi-regulated geographies creates structural revenue diversification and higher entry barriers for competitors. Regulatory approvals and distributor relationships underpin recurring export revenue and support long-term growth and margin stability versus pure domestic generics.
Improving Cash Generation And Revenue GrowthSteady top-line growth combined with a rebound in free cash flow signals improved operating leverage and cash conversion potential. Sustained cash generation reduces financing needs, funds working capital and R&D, and supports reinvestment into higher-value formulations over the medium term.
Bears Say
Volatile Margins And EarningsHistoric margin and earnings volatility reduce predictability of sustained profitability in a generics/finished-dosage business. This makes planning for capacity, pricing negotiations, and long-term contracts harder, and can amplify downside during pricing or raw-material cost pressure.
Choppy Cash ConversionIrregular operating cash flow and swings in free cash flow suggest working-capital sensitivity or lumpy receipts from exports. This variability can force short-term financing, delay capex or product launches, and raise execution risk for sustained growth initiatives.
Operating-profit Clarity IssuesAtypical EBITDA-to-EBIT relationships point to non-standard operating items or cost classification changes, complicating assessment of core margin sustainability. This opacity hampers forecasting, makes benchmarking versus peers harder, and can obscure true operating leverage trends.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹118.35 and its highest was ₹552.90 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹49.57B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is Oct 23, 2026 which is in 78 days.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Currently, no data Available
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.32%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 106,056,220 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.
Technical Analysis
Innova Captab Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―